Clearsense – a healthcare data analytics and data management solutions provider – raised $50 million in Series D funding.
HealthQuest Capital led the investment round with participation from Health Catalyst Capital and UPMC Enterprises.
Including the latest funding round, Clearsense has raised more than $100 million in funding to date. The company previously raised $30 million from Health Catalyst in 2021.
Commenting in the funding news announcement, Gene Scheurer, CEO of Clearsense, said: “This investment into our organization further strengthens our mission to unlock the full potential of healthcare data by delivering solutions that empower data confidence and enable data-driven decision-making to achieve better outcomes.” “We’re elated to begin a relationship with HealthQuest, which shares the same vision: Transforming healthcare.”
HealthQuest Capital is a growth capital firm investing in commercial-stage healthcare technology companies that optimize healthcare delivery, improve outcomes, and reduce costs. The San Francisco Bay Area-based venture capital firm has invested more than $700 million in healthcare technology companies to date. Its latest investment portfolio includes – Nomad Health, Lunit, Thirty Madison, EverlyWell, TigerConnect, Perspectum, Bardy Diagnostics, BioIQ, and Avizia.
Anthony Williams, a partner at HealthQuest, said: “We seek to partner with transformative companies that meaningfully improve patient outcomes and economics across the healthcare ecosystem. Clearsense’s platform accomplishes both of these objectives by enabling hospitals and health systems to utilize their data as a valuable asset. We’re excited to partner with the company as it continues its impressive growth trajectory.”
According to our funding database, healthcare data analytics companies have raised approximately $20 billion in funding to date.
The latest funding round in the healthcare data analytics space includes:
Elaborate, a digital assistant for care providers to analyze and understand lab results in real-time, raised $10 million in Seed funding.
Biofourmis, a provider of AI-powered predictive healthcare data analytics solutions for clinicians, raised $300 million in Series D funding. General Atlantic and CVS Health led the investment round with participation from SoftBank Vision Fund 2, Openspace Ventures, Mass Mutual Ventures, Sequoia Capital, and EDBI.
23andMe, a provider of direct-to-consumer DNA testing and genomics data analytics solutions, received $300 million in funding from GlaxoSmithKline.